Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2024-01-16 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Series B Fund Raise by partner, Stalicla SA
Share Issue/Capital Change Classification · 99% confidence The document begins with 'RNS Number : 8899Z' and contains information typical of a regulatory news service announcement, including a date (16 January 2024) and company details. The content discusses a partner's financing round and updates on joint drug development programs, which is a material event for the company. The footer explicitly states, 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This structure strongly indicates a general regulatory announcement that doesn't fit a more specific category like Earnings Release (ER) or Director's Dealing (DIRS). Since it is a general regulatory announcement distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). The document length (4691 chars) is moderate, but the content is purely an announcement of external news/partner activity, not a full report.
2024-01-16 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed for Evgen Pharma PLC, dated December 29, 2023. This form is used to report changes in significant share ownership (crossing thresholds) by an entity (AXA Investment Managers S.A.). This type of filing specifically relates to changes in major shareholdings, which directly corresponds to the definition for Major Shareholding Notification (MRQ). The presence of the RNS number and the mention of RNS/FCA confirms it is a regulatory disclosure, but MRQ is the most specific category for this content.
2023-12-29 English
Directorate Changes
Board/Management Information Classification · 100% confidence The document is a formal announcement released via RNS (Regulatory News Service) on December 22, 2023. The primary content details 'Directorate Changes,' specifically the appointment of a permanent CFO (Toni Hänninen) and the retirement of a Non-Executive Director (Susan Clement-Davies). This directly corresponds to the definition of 'Board/Management Information' (MANG). Although it is distributed via RNS, the specific subject matter is management changes, making MANG the most precise classification over the general RNS fallback.
2023-12-22 English
Upcoming conferences
Report Publication Announcement Classification · 99% confidence The document is identified by the 'RNS Number : 1598T' header and contains information about the company's executive team attending upcoming investor conferences and events. This type of announcement, which informs the market about corporate activities but is not a core financial report (like 10-K, IR, or ER), fits best under the general regulatory announcement category. Since it is a formal notification distributed via RNS (Regulatory News Service) and doesn't fit the specific definitions for AGM-R, ER, DIV, DIRS, etc., the most appropriate classification is the general Regulatory Filings fallback code.
2023-11-13 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half Year Report' for Evgen Pharma plc for the period ended 30 September 2023. It contains detailed operational highlights, financial highlights (including post-tax loss and cash balances), and a comprehensive management discussion of the company's pipeline and business development. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2023
2023-10-31 English
Erasmus Medical Center begins glioblastoma studies
Regulatory Filings Classification · 98% confidence The document starts with an RNS Number (3145R) and a date, indicating a regulatory announcement. The content details a clinical study commencement for a drug (SFX-01) and a minor administrative update (Nominated Adviser name change). This type of broad, timely corporate news release that doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or DIV) is characteristic of a general regulatory filing or news service announcement. Since it is a formal announcement distributed via RNS, and it is not a specific report like an Annual Report (10-K) or an Earnings Release (ER), the most appropriate classification is the general Regulatory Filings category (RNS). The document length is moderate (5726 chars), but the content is purely informational news, not a detailed financial report.
2023-10-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.